Goodwin is advising the Official Committee of Unsecured Creditors on the procedure. Novan, Inc. (Nasdaq: NOVN) and its wholly owned subsidiary, EPI Health, LLC, announced that it...
You must be a Standard 1 Year member to access this content.
Goodwin advised BrainStorm on the offering, and Ellenoff Grossman advised the placement agent. BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) announced its registered direct offering of 4,054,055...
You must be a Standard 1 Year member to access this content.
Goodwin advised OncoC4 on the deal. OncoC4 announced its agreement with BioNTech SE pursuant to which BioNTech receives an exclusive worldwide license to co-develop and commercialize OncoC4’s...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised EQRx on the deal while White & Case LLP advised CM Life Sciences III Inc. EQRx, Inc. announced its definitive merger agreement with CM...
You must be a Standard 1 Year member to access this content.
Goodwin Procter LLP advised Cathay Health, Polaris Partners, and Newpath Partners on the deal. Cathay Health, Polaris Partners, and Newpath Partners lead the Kojin Therapeutics’ $60 Million Series...
You must be a Standard 1 Year member to access this content.
Goodwin Procter LLP advised Vascular Biogenics Ltd. on the deal. Vascular Biogenics Ltd. (“VBL Therapeutics” or the “Company”) (NASDAQ: VBLT) announced the closing of its underwritten public offering...
You must be a Standard 1 Year member to access this content.
